Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141782

registered interest
date	24/07/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Applications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, which organisations his Department has advertised information to outlining that visa applicants wishing to extend their leave to remain will not be penalised in cases where they have had to wait for an appointment at a UK Visa and Citizenship Application Services service point; and how that information has been publicised.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	281737
answer	answer is ministerial correction date of answer 03/09/2019 answer text <p>Information about biometric enrolment timescales for UKVCAS customers is publicised to applicants as part of the online application process on GOV.UK.</p><p>If the applicant does not enrol biometrics within this period they are sent a reminder and are given a further period in which to enrol.</p><p>If the applicant does not enrol their biometrics within these timescales their application is deemed as invalid and could be rejected. Prior to any action to reject the application UKVI would check to confirm whether an appointment to enrol has been booked. UKVI would not reject an application because the applicant had to wait for an appointment</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/09/2019 16:06:28 answering member 4455 label Biography information for Seema Kennedy
tabling member	4036 label Biography information for Luciana Berger

1140957

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of the drug metamizole.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280288
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280289 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1140958

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Spain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will have discussions with his Spanish counterpart on the effect of dispensing metamizole to (a) UK and (b) Spanish residents in Spain.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280289
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1140960

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Spain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to raise awareness of the potential side-effects of the drug metamizole among UK citizens and tourists in Spain.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280290
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280289 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1135177

registered interest
date	27/06/2019
answering body	Ministry of Housing, Communities and Local Government
answering dept id	7
answering dept short name	Housing, Communities and Local Government
answering dept sort name	Housing, Communities and Local Government
hansard heading	Garden Communities
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Housing, Communities and Local Government,with reference to the Loneliness Strategy, what steps he is taking to work with Homes England to incorporate community cohesion as part of the support offered to existing and future garden communities.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	270355
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>Across England, we are currently supporting 48 locally-led garden communities, to be exemplars of high quality, good design and best practice.</p><p>These places will encourage strong social connections through vibrant spaces with mixed community use and healthy places that take a holistic approach to tackling wellbeing priorities. To date we have provided £38 million in capacity funding which includes early support to fund dedicated staff teams, key studies and assessments to underpin delivery of our garden towns and villages.</p><p>My Department and Homes England are exploring an effective means of sharing learning and good practice on tackling loneliness and social isolation through design and planning approaches with professional and accredited bodies.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 02/07/2019 14:38:11 answering member 4495 label Biography information for Kit Malthouse
tabling member	4036 label Biography information for Luciana Berger